Former AstraZeneca executive accused of insider trading over Daiichi cancer drug deal

A former AstraZeneca communications executive was accused of insider trading in connection with a partnership with Daiichi Sankyo to develop and market a cancer drug, according to a lawsuit filed by the U.S. Securities and Exchange Commission.

Hugues Pierre Joublin, 54, was employed as the global head of corporate affairs for oncology when he learned in early March 2019 that AstraZeneca was holding confidential talks with Daiichi Sankyo about a global development and commercialization agreement. Within a week, he purchased 500 American Depository Shares of Daiichi.

Later that month, after the deal was announced, Joublin sold the securities, which rose 24% in value, for a $5,000 profit. At the time, he was responsible for drafting public communications, including the preparation of a document about the deal, a communications plan, a press release, and draft internal documents, according to the lawsuit, which was filed in a federal court in New York.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In